CBDA is a naturally occurring phytocannabinoid biosynthesised in the trichomes of Cannabis sativa L. The compound forms when the enzyme CBDA synthase oxidatively cyclises cannabigerolic acid (CBGA), the so-called "mother cannabinoid" that serves as the common precursor to the three major cannabinoid acid lineages. Raw plant tissue , including fresh leaves and uncured flower , contains CBDA as the dominant cannabinoid fraction, often at concentrations far exceeding those of its neutral counterpart CBD.
Chemically, CBDA shares CBD's core resorcinyl and terpenoid scaffold but carries an additional carboxyl group (–COOH) at the C-2 position of the cyclohexane ring. This carboxyl group is lost as carbon dioxide during decarboxylation (typically above approximately 120 °C), yielding CBD. Because of this instability, CBDA is not retained in most heated preparations and is therefore largely absent from smoked, vaped, or conventionally extracted cannabinoid products.
Pharmacologically, CBDA does not bind with meaningful affinity to the canonical CB1 or CB2 receptors of the endocannabinoid system. Early preclinical research , primarily in cell culture and rodent models; has examined its interaction with 5-HT1A serotonin receptors and cyclooxygenase-2 (COX-2) enzyme activity, as well as its reported agonist activity at TRPA1 ion channels. These findings remain at a preliminary stage; peer-reviewed human clinical trial data on CBDA as an isolated compound are limited as of mid-2025, and no regulatory body has approved CBDA as a medicine in its own right.
Under the Australian Poisons Standard, CBDA derived from low-THC hemp is not separately scheduled where it meets the Schedule 4 CBD or Schedule 1 hemp-seed exemption conditions; however, CBDA sourced from cannabis varieties exceeding the permitted THC thresholds falls within the broader cannabis scheduling framework administered by the Therapeutic Goods Administration (TGA). Researchers wishing to work with CBDA in a clinical context are subject to the standard TGA Special Access Scheme (SAS) and Authorised Prescriber pathways that govern unapproved cannabinoid substances.
Sources: